New therapies for systemic lupus erythematosus

Rheumatic Disease Clinics of North America

Volumn 26, Issue 2, 2000, Pages 389-406

  Strand, Vibeke ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; B7 ANTIGEN; BROMOCRIPTINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA ANTIBODY; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PRASTERONE; SEX HORMONE; THALIDOMIDE; THIAMAZOLE;

COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

EID: 0034111882     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70145-9     Document Type: Article

References (103)

1. Abrams J: Presented at the Conference on Innovative Therapies in Autoimmune Diseases, Washington, DC, April 4–5, 1997
2. J. Alcocer-Varela L. Llorente D. Alarcon-Segovia Immunoregulatory circuits and potential treatment of connective tissue diseases Int Arch Allergy Immunol 111 1996 348 354
3. M. Al-Janadi A. Al-Dalaan S. Al-Balla IL-10 secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10 dependent CD4+CD45RO+ T-cell-B-cell antibody synthesis J Clin Immunol 16 1996 198 207
4. J. Alvarez-Nemegyei A. Covarrubias-Cobos F. Escalante-Triay Bromocriptine in systemic lupus erythematosus: A double blind, randomized placebo controlled study Lupus 7 1998 414 419
5. L.D. Apelgren D.L. Bailey R.L. Fouts The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL 1pr/1pr mice Cell Immunol 173 1996 55 63
6. M. Blank I. Krause D. Buskila Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells Cell Immunol 162 1995 114 122
7. Boletis JN, Boki C, Michael S, et al: Comparative study of pulse treatment with cyclophosphamide or immunoglobulin to sustain the remission of lupus nephritis. Presented at the Fourth European Conference on SLE, Vienna, January 23–26, 1999
8. W.A. Briggs M.J. Choi P.J. Scheel Successful mofetil treatment of glomerular disease Am J Kidney Dis 31 1998 213 217
9. R.A. Brodsky M. Petri B.D. Smith Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease Ann Intern Med 129 1998 1031 1035
10. R. Burt A.E. Traynor R. Pope Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation Blood 92 1998 3505 3514
11. CellCept (mycophenolate mofetil capsules) package insert. Roche Laboratories 1995
12. Y. Chuzhin B. Reddy L. Budhai Prolonged survival in murine SLE by adenoviral mediated CTLA41g gene transfer Arthritis Rheum 41 suppl 1998 S140
13. D. Daikh D. Wofsy The immune response to anti-B7 antibodies is dose dependent: Low doses elicit a potent response while high doses block the immune response Arthritis Rheum 39 suppl 1996 S106
14. D.I. Daikh D. Wofsy Reversal of advanced murine lupus nephritis with combined CTLA4Ig and cyclophosphamide Arthritis Rheum 41 suppl 1998 S140
15. I.D. Daikh B. Palmer B. Finck CTLA41g inhibits cytokine production by CD4 T cells in NZB/NZW lupus-prone mice Arthritis Rheum 39 suppl 1996 S106
16. L.D. Alpelgren D.C. Bailey R.L. Fouts The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice Cell Immunol 173 1996 55 63
17. J.C. Davis H. Austin D. Boumpas A pilot study of 2′chloroxyadenosine (2-CdA) in the treatment of systemic lupus erythematosus associated glomerulonephritis Arthritis Rheum 41 1998 335 343
18. J.C. Davis S. Manzi C. Yarboro Recombinant human DNase (rhDNase) in patients with lupus nephritis. DNAse for lupus nephritis Lupus 8 1999 68 76
19. R. Derksen Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus Semin Arthritis Rheum 27 1998 335 347
20. S. DeVita G.F. Ferraccioli Di Poi F. High intravenous immunoglobulin therapy for rheumatic diseases: Clinical relevance and personal experience Clin Exp Rheumatol 14 1996 85 92
21. M.A. Dooley P.H. Nachman K.K. Satterly Mycophenolate mofetil therapy in resistant or relapsing diffuse proliferative lupus nephritis following cyclophosphamide therapy Arthritis Rheum 40 suppl 1997 S58
22. K.B. Elbourne D. Keisler R.W. McMurray Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus Lupus 7 1998 420 427
23. C. Evans J.D. Whalen S.C. Ghivizzani Gene therapy in autoimmune diseases Ann Rheum Dis 57 1998 125 127
24. H. Fillit S. Shibata T. Sasaki Autoantibodies to the protein core of vascular basement membrane heparin sulfate proteoglycan in systemic lupus erythematosus Autoimmunity 14 1993 243 249
25. B.K. Finck P.S. Linsley D. Wofsy Treatment of murine lupus with CTLA41g Science 265 1994 1225 1227
26. S. Fujieda K. Zhang A. Saxon IL-4 plus CD40 monoclonal antibody induces human B cells g subclass-specific isotype switch: Switching to g1 g4, but not g2 J Immunol 155 1995 2318 2328
27. sm) in patients with chronic ITP [abstract] Blood 92 1998 suppl
28. A. Grammer M.C. Bergman Y. Miura The CD40 ligand expressed by human B cells costimulates B cell responses J Immunol 154 1995 4996 5010
29. G. Grondal H. Kristjansdottir K.H. Traustadottir IL-10 production and apoptosis in SLE patients and their spouses in Icelandic SLE-multicase families Arthritis Rheum 41 suppl 1998 S283
30. A. Guglielmotti L. Aquilini E. D'Onofrio Bindarit prolongs survival and reduces renal damage in NZB/W lupus mice Clin Exp Rheumatol 16 1998 149 154
31. V.G. Hale J.V. Braum L. Richardson Recombinant human DNAse (rhDNAse) for SLE nephritis: Characterization of safety, tolerance and disposition following systemic administration Arthritis Rheum 39 suppl 1996 S254
32. Hepburn B: Presented at the Conference on Innovative Therapies in Autoimmune Diseases, Washington, DC, April 4–5, 1997
33. B. Hepburn R. Furie J. Cash Reduction of anti-DS DNA antibodies using LJP 394 in patients with lupus Arthritis Rheum 39 suppl 1996 S307
34. A. Ho L. Magder M. Petri The effect of azathioprine/mycophenolate on systemic lupus erythematosus activity Arthritis Rheum 41 suppl 1998 S281
35. R.F. Holocombe C. Elder R.E. Wolf 2-Chlorodeoxyadenosine (2-CdA) in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases Arthritis Rheum 38 suppl 1995 S304
36. Immediate and longer term effects on anti ds DNA Abs by treatment with LJP 394
37. H. Ishida T. Muchamuel S. Sakaguchi Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice J Exp Med 179 1994 305 310
38. L. Jacob M.A. Lety D. Luvard Binding of a monoclonal anti DNA autoantibody to identical protein(s) present at the surface of several human cell types involved in lupus pathogenesis J Clin Invest 75 1985 315 317
39. D.S. Jones P.A. Barstad M.J. Feild Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis J Med Chem 38 1995 2138 2144
40. D. Jumper Y. Nishioka L.S. Davis Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands J Immunol 155 1995 2369 2378
41. Y. Kalechman U. Gafter J.P. Da Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101 J Immunol 159 1997 2658 2667
42. K. Kato E. Santana-Sahagun L.Z. Rassenti Elevated soluble CD40-ligand (CD154) in plasma of patients with systemic lupus erythematosus Arthritis Rheum 41 suppl 1998 S71
43. D. Klinman K. Elias S. Shak DNAse treatment of DNA-anti DNA immune complexes in SLE Arthritis Rheum 39 suppl 1996 S307
44. S. Kreidstein M. Urowitz D.D. Gladman Hormone replacement therapy in systemic lupus erythematosus J Rheumatol 24 1997 2149 2152
45. R.G. Lahita C.Y. Cheng C. Monder Experience with 19 nortestosterone in the therapy of systemic lupus erythematosus: Worsened disease after treatment with 19 nortestosterone in men and lack of improvement in women J Rheumatol 19 1992 547 555
46. M.L. Lee F. Spertini A. Leimgruber Updated phase 1 clinical results with an idiotypic vaccine (3E 10) for systemic lupus erythematosus (SLE) Arthritis Rheum 8 suppl 1995 S303
47. P.S. Linsley J.A. Ledbetter The role of the CD28 receptor during T cell responses to antigen Annu Rev Immunol 11 1993 191 212
48. L. Llorente W. Zou Y. Lewy Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus J Exp Med 181 1995 839 844
49. L. Llorente C. Garcia-Padilla Y. Richaud-Patin Treatment of systemic lupus erythematosus with an anti-interleukin-10 monoclonal antibody Arthritis Rheum 41 suppl 1998 S109
50. A.M. Marmont Stem cell transplantation for severe autoimmune diseases: Progress and problems Haematologica 83 1998 733 743
51. A.M. Marmont A. Tyndall A. Gratwohl Hematopoietic precursor cell transplants for autoimmune diseases Lancet 345 1995 978
52. Matis L: Presented at the Conference on Innovative Therapies in Autoimmune Diseases, Washington, DC, April 4–5, 1997
53. L.A. Matis S.A. Rollins Complement-specific antibodies: Designing novel anti-inflammatories Nature Med 1 1995 839 842
54. R. McMurray D. Keisler K. Kanuckel Prolactin influences autoimmune disease activity in the female B/W mouse J Immunol 147 1992 3780 3787
55. R.W. McMurray K.B. Elbourne A. Iagoo Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus J Rheumatol 25 1998 2364 2370
56. P.A. McSweeney R.A. Nash R. Storb Autologous stem cell transplantation for autoimmune diseases: Issues in protocol development J Rheumatol 48 suppl 1997 79 84
57. C.R. Meier M.C.J.M. Sturkenboom A.S. Cohen Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus J Rheumatol 25 1998 1515 1519
58. C. Mohan Y. Shi J.D. Laman Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis J Immunol 154 1995 1470 1480
59. C. Mok C.S. Lau C.T.K. Ho Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus Scand J Rheumatol 27 1998 342 346
60. A.L. Moreira E.P. Sampaio A. Zmuidzinas Thalidomide exerts its inhibitory action on TNFα by enhancing mRNA degradation J Exp Med 177 1993 1675
61. E. Mozes R. Segal Z. Sthoeger Modulation of experimental systemic lupus erythematosus Isr J Med Sci 32 1996 19 21
62. E. Mozes H. Zinger L.D. Kohn Spontaneous autoimmune disease in (NZB/ NZW)F1 mice is ameliorated by treatment with methimazole J Clin Immunol 18 1998 106 113
63. M. Musso G. Porretto A. Crescimanno Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome Lupus 7 1998 492 794
64. A. Nakajima M. Azuma S. Kodera Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule Eur J Immunol 13 1995 179 200
65. J. Davis N. Austin D. Boumpas A pilot study of clidaribine 2 chlorodeoxyadenosine in the treatment of systemic lupus erythematosus associated with glomerulonephritis Arth Rheum 41 1998 335 343
66. Y. Park S.K. Lee D.S. Kim Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus Clin Exp Rheumatol 16 1998 283 288
67. N. Pashinian D.J. Wallace J.R. Klinenberg Mycophenolate mofetil for systemic lupus erythematosus Arthritis Rheum 41 suppl 1998 S110
68. M. Petri C. Robinson Oral contraceptives and systemic lupus erythematosus Arthritis Rheum 40 1997 797 803
69. M. Petri R. Lahita J. McGuire Results of the GL701 (DHEA) multicenter steroid sparing SLE study Arthritis Rheum 40 suppl 1997 S327
70. N.K.A. Prasad G. Papoff A. Zeuner Therapeutic preparations of normal polyspecified IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the fas apoptotic pathway J Immunol 161 1998 3781 3790
71. C.T. Ravirajan Y. Wang L. Matis Effect of anti-IL10 and anti-C5 on human anti-ds DNA antibody induced kidney damage Arthritis Rheum 41 suppl 1998 S177
72. E. Raz J. Dudler M. Lotz Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery Lupus 4 1995 286 292
73. H. Reiser M.J. Stadecker Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases N Engl J Med 335 1996 1369 1375
74. G. Remuzzi G. Vigano E. Gotti Bindarit, a new potential therapeutic agent for lupus nephritis: A pilot study Lupus 4 1995 99
75. J. Rönnelid B. Nillson Immune complexes from SLE sera induce IL-10 production. A possible vicious circle maintaining B cell hyperactivity in SLE Arthritis Rheum 41 suppl 1998 S67
76. J. Rovensky E. Jurankova L. Rauova Relationship between endocrine, immune and clinical variables in patients with systemic lupus erythematosus J Rheumatol 24 1997 2330 2334
77. L. Sammaritano K. Patterson M. Lockshin Current use of ERT in postmenopausal systemic lupus erythematosus patients: Increase since inception of the SELENA trial Arthritis Rheum 41 suppl 1998 S65
78. J. Sanchez-Guerrero E.W. Karlson M.H. Liang Past use of oral contraceptives and the risk of developing systemic lupus erythematosus Arthritis Rheum 40 1997 804 807
79. E.I. Sato L.S.S. Assis A. Furtado Long-term thalidomide therapy for cutaneous lesions of systemic lupus erythematosus (SLE) Arthritis Rheum 39 suppl 1996 S253
80. Schwartz K: Potential Treatment of SLE: DHEA-Proposed Responder Analysis. Presented at the Conference on Innovative Therapies in Autoimmune Diseases, Washington, DC, April 4, 1997
81. D. Scott J. Balow Austin H. III A pilot study of cladribine (2′-chlorodeoxyadenosine) in lupus nephritis Arthritis Rheum 38 suppl 1995 S304
82. P.P. Sfikakis C.S. Via Expression of CD28, CTLA4, CD80 and CD86 molecules in patients with autoimmune rheumatic diseases: Implications of immunotherapy Clin Immunol Immunopathol 83 1997 195 198
83. Y. Shoenfeld I. Krause M. Blank New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation Ann Rheum Dis 56 1997 5 11
84. J.O. Shroider R.A. Zeuner H.H. Euler High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study J Rheumatol 23 1996 71 75
85. Spertini F, Leimgruber A, Morel B, et al: Idiotypic vaccination in lupus nephritis with a murine anti-dsDNA antibody. J Rheum 27: in press
86. R.J. Stevens C. Andujar C. Edwards Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus Arthritis Rheum 39 suppl 1996 S253
87. V. Strand M. Lee Intravenous immunoglobulin (IVIg) in the treatment of autoimmune diseases Strand V. Scott D.L. Simon L.S. Novel Therapeutic Agents for the Treatment of Autoimmune Diseases 1997 Dekker New York 235 256
88. K. Takeuchi M. Inaba S. Miyashima A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/1pr mice Blood 91 1998 4616 4623
89. S. Tseng G. Pak K. Washenik Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses J Am Acad Dermatol 35 1996 969 979
90. R.K. Vakkalanka K.A. Kirou C. Raman Kinetics of CD40 ligand mRNA expression in systemic lupus erythematosus patients and healthy controls Arthritis Rheum 41 suppl 1998 S235
91. R.K. Vakkalanka C. Woo K.A. Kirou Soluble CD40 ligand (sCD40L) in sera from patients with SLE is present at concentrations that can mediate B cell activation Arthritis Rheum 41 suppl 1998 S235
92. Van Vollenhoven R.F. H.O. McDevitt Studies of the treatment of nephritis in NZB/NZW mice with dehydroepiandrosterone Arthritis Rheum 35 suppl 1992 S207
93. van Vollenhoven R.F. E.G. Engleman J.L. McGuire Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial Arthritis Rheum 38 1995 1826 1831
94. Van Vollenhoven R.F. E.G. Engleman J.L. McGuire An open study of dehydroepiandrosterone in systemic lupus erythematosus Arthritis Rheum 37 1994 1305 1309
95. D. Verthelyi N. Dybdal K.A. Elias DNAse treatment does not improve the survival of lupus prone NZB × NZW F1 mice Lupus 7 1998 223 230
96. S.E. Walker S.H. Allen R.W. Hoffman Review: Prolactin a stimulator of disease activity in systemic lupus erythematosus Lupus 4 1995 3 9
97. 1 mice after treatment with a blocking monoclonal antibody specific for complement component C5 Proc Natl Acad Sci USA 93 1996 8563 8568
98. Y. Wang O. Hu J. Kristan Subcutaneous administration of anti-C5 monoclonal antibody induces systemic complement inhibition and ameliorates immune complex mediated inflammatory responses Arthritis Rheum 39 suppl 1996 S245
99. R.H. Weisbart D.T. Noritake A.L. Wong A conserved anti DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus J Immunol 144 1990 2653 2658
100. M.H. Weisman H.G. Blustein C.M. Berner Reduction in circulating dsDNA antibody titer after administration of LJP 394 J Rheumatol 24 1997 314 318
101. R.C. Williams C.C. Malone G. Fry Affinity columns containing anti-DNA Id+ human myeloma proteins adsorb human epibodies from intravenous gamma globulin Arthritis Rheum 40 1997 683 693
102. M.J. Yellin V. D'Agati G. Parkinson Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides Arthritis Rheum 40 1997 124 134
103. C. Zoja G. Corna M. Morigi Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease Kidney Int 53 1998 726 734